2,536 reports of this reaction
3.2% of all ANASTROZOLE reports
#4 most reported adverse reaction
ALOPECIA is the #4 most commonly reported adverse reaction for ANASTROZOLE, manufactured by ANI Pharmaceuticals, Inc.. There are 2,536 FDA adverse event reports linking ANASTROZOLE to ALOPECIA. This represents approximately 3.2% of all 80,386 adverse event reports for this drug.
Patients taking ANASTROZOLE who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is moderately reported among ANASTROZOLE users, representing a notable but not dominant share of adverse events.
In addition to alopecia, the following adverse reactions have been reported for ANASTROZOLE:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 2,536 FDA reports for ANASTROZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 3.2% of all adverse event reports for ANASTROZOLE, making it a notable side effect.
If you experience alopecia while taking ANASTROZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.